Nephron Pharmaceuticals CEO Lou Kennedy spoke to local reporters in the company’s home state of South Carolina on March 17, 2020, describing the company’s efforts to increase production of its inhalation solutions and suspensions to meet demand during the COVID-19 pandemic.
Nephron produces its own inhalation products; including albuterol, ipratroprium bromide, and budesonide; and offers contract manufacturing. Demand for those products so far in March is up 48% over normal levels, Kennedy told reporters.
According to a local newspaper, Nephron has requested regulatory approval to add six production lines to its existing eight lines, allowing for an increase from 110 million doses per month to 160-170 million doses per month. Kennedy told the paper that she is scheduled to hold a meeting with the FDA to discuss the expansion this month.
Read a Nephron Pharmaceuticals summary of news reports.
